Literature DB >> 2895345

Thalidomide for graft-versus-host disease.

G B Vogelsang, G W Santos, O M Colvin, T Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2895345     DOI： 10.1016/s0140-6736(88)91690-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation.

Authors:  A G Tzakis; K Abu-Elmagd; J J Fung; E J Bloom; B Nour; F Greif; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 2.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

3.  Thalidomide--the way forward.

Authors:  J M Gardner-Medwin; R J Powell
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

4.  Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.

Authors:  Z Cao; W R Joseph; W L Browne; K G Mountjoy; B D Palmer; B C Baguley; L M Ching
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

Review 5.  The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview.

Authors:  Margherita Boieri; Pranali Shah; Ralf Dressel; Marit Inngjerdingen
Journal:  Front Immunol       Date:  2016-08-30       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.